Cargando…
Patient-Derived Xenografts of High-Grade Serous Ovarian Cancer Subtype as a Powerful Tool in Pre-Clinical Research
SIMPLE SUMMARY: Patient-derived xenografts (PDXs) have gained popularity as a model system in anti-cancer drug development. PDXs are established by the transfer of patient tumors directly into mice without prior in vitro manipulation, assuming that these models closely resemble patient tumors. Howev...
Autores principales: | Cybula, Magdalena, Wang, Lin, Wang, Luyao, Drumond-Bock, Ana Luiza, Moxley, Katherine M., Benbrook, Doris M., Gunderson-Jackson, Camille, Ruiz-Echevarria, Maria J., Bhattacharya, Resham, Mukherjee, Priyabrata, Bieniasz, Magdalena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699796/ https://www.ncbi.nlm.nih.gov/pubmed/34944908 http://dx.doi.org/10.3390/cancers13246288 |
Ejemplares similares
-
Increased expression of BRD4 isoforms long (BRD4-L) and short (BRD4-S) promotes chemotherapy resistance in high-grade serous ovarian carcinoma
por: Drumond-Bock, Ana Luiza, et al.
Publicado: (2023) -
Multi-kinase targeted therapy as a promising treatment strategy for ovarian tumors expressing sfRon receptor
por: Wang, Luyao, et al.
Publicado: (2020) -
The role of distinct BRD4 isoforms and their contribution to high-grade serous ovarian carcinoma pathogenesis
por: Drumond-Bock, Ana Luiza, et al.
Publicado: (2021) -
Cloning BRD4 long isoform into overexpression vectors for stable overexpression of BRD4-L in mammalian cells
por: Drumond-Bock, Ana Luiza, et al.
Publicado: (2022) -
Patient-derived tumor models are attractive tools to repurpose drugs for ovarian cancer treatment: pre-clinical updates
por: Cybula, Magdalena, et al.
Publicado: (2022)